Association between Bone Marrow Mesenchymal Stem Cell Characterization and Taking Inotropic Drugs in Patients with Severe Left Ventricular Dysfunction After Off-pump Bypass Surgery

Background and Aim: Left ventricular dysfunction is a frequent complication after coronary artery bypass graft (CABG) and is often treated with inotropic drugs to achieve suitable hemodynamic status. Bone marrow-derived mesenchymal stem cells (BMSCs) have potential effects on cardiac function. In this study, we aimed to identify the predictor role of MSCs in taking inotropic drugs in patients with severe left ventricular dysfunction undergoing CABG. Methods: The study included 30 patients who underwent off-pump CABG at Afshar Hospital and Seyed Al-Shohada Hospital. For investigating the possible association of BMSCs proliferation rate with taking inotropic drugs, the bone marrow samples aspired from patients' sternum during surgery. MSCs were isolated and counted after 4, 7, and 14 days using trypan-blue color, and then doubling times were calculated. Results: After cardiac surgery, the number of female patients who take inotropic drugs was significantly higher than men. Our data showed that the BMSCs doubling time in female patients who received inotropic drugs was less than that of male patients who received inotropic drugs (p < 0.05). Conclusion: Based on this investigation, we concluded that there was a clear relevance between the MSCs' doubling time and the inotropic drug requirements in patients who received inotropic drugs.